Coire Weathers, MD
Psychiatry · Boise, IDNPI 1437319662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 34.8% of the total. Reporting peaked in 2019 at $262 and has fallen 64.1% since, to $94 in 2025.
Across 45 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$248
- AbbVie$140
- Alkermes, Inc.$79
- E.r. Squibb & Sons, L.L.C.$71
- Sunovion Pharmaceuticals Inc.$46
- Takeda Pharmaceuticals U.S.A., Inc.$36
- plus $91 from 4 others
What the payments were for
- Food & beverage$711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 21 | $248 |
| AbbVie(2 entities) | 7 | $140 |
| Alkermes, Inc. | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Indivior Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
How this compares
$711 in reported general payments places this provider in the 75th percentile of 98 psychiatry providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 14 | $309 |
| Bupropion XlBupropion Hcl | 12 | $241 |
| Duloxetine Hcl | 11 | $222 |
| Lithium Carbonate ErLithium Carbonate | 13 | $208 |
| Quetiapine Fumarate | 16 | $168 |
| Fluoxetine Hcl | 28 | $104 |
| Lamotrigine | 13 | $92 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Boise
- Richard PinesBoise$4K
- David ThompsonBoise$1K
- John CarrBoise$1K
- Marc BostickBoise$1K
- Rick YavruianBoise$1K
- Matthew AckleyBoise$774
- Daniel KrashinBoise$298
- Charles NovakBoise$198
- Alex WillsBoise$152
- Nicole FoxBoise$150
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.